Understanding the Opioid Pathway in Schizophrenia and Bipolar I Disorder

When people think about schizophrenia or bipolar I disorder, the conversation often focuses on familiar brain chemicals such as dopamine, serotonin, norepinephrine, and glutamate. These systems have shaped how clinicians understand symptoms, develop medications, and explain serious mental illness. This article explores another biologic system that may also be relevant: the opioid pathway.

The opioid pathway is often discussed in the context of pain medications, substance use, and overdose risk. However, opioid receptors are also involved in reward, stress response, appetite, impulsivity, motivation, and dopamine release. These functions are clinically important because schizophrenia and bipolar I disorder can involve not only psychosis or mood instability, but also changes in behavior, cravings, self-harm risk, substance use vulnerability, and metabolic health.

In a Pharmaphorum article, Dr. Richard L. Price discusses why the opioid pathway deserves more attention in serious mental illness. The article explains that μ-, κ-, and δ-opioid receptors may influence several areas that are commonly affected in schizophrenia and bipolar I disorder, including reward processing, emotional regulation, impulsive behavior, and stress sensitivity. Looking at these conditions through this broader lens may help clinicians better understand symptoms and comorbidities that do not fit neatly into traditional dopamine- or serotonin-based explanations.

In schizophrenia, the article notes that opioid-system changes have been described in the scientific literature for decades. These changes may relate to dopamine regulation, stress sensitivity, dysphoria, and reward-driven behavior. Clinically, this matters because many people living with schizophrenia also experience co-occurring challenges such as alcohol use, self-injury, gambling problems, risky behavior, or opioid use. These concerns are not separate from psychiatric care; they can shape illness course, safety, and treatment planning.

The article also discusses the relevance of the opioid pathway in bipolar I disorder. Bipolar I disorder can involve manic or mixed episodes, mood instability, impulsivity, and reward-driven behavior. The opioid system may be one biologic pathway involved in some of these patterns. The article describes a bidirectional relationship in which mood symptoms may increase vulnerability to opioid misuse, while opioid exposure may also worsen or precipitate mood symptoms in some cases.

One treatment-related example discussed in the article is olanzapine/samidorphan, a medication that combines the antipsychotic olanzapine with samidorphan, a μ-opioid receptor antagonist. Olanzapine has long been used in schizophrenia and bipolar I disorder, but its use can be limited by weight gain and metabolic side effects. Samidorphan was designed to help mitigate some of the weight and metabolic effects associated with olanzapine. This does not mean the medication is appropriate for every patient, but it illustrates how opioid-receptor biology may be relevant to psychiatric treatment development.

The article also describes real-world research suggesting that patients taking olanzapine/samidorphan may have fewer emergency room visits, fewer hospitalizations, and shorter inpatient stays compared with some patients taking other oral atypical antipsychotics or olanzapine alone. These findings are not proof of causation, and they should not be interpreted as a guarantee of benefit. However, they raise clinically important questions about whether treatment approaches involving opioid-receptor modulation may affect factors that contribute to acute psychiatric crises, such as impulsivity, cravings, self-injury, substance use vulnerability, or other destabilizing behaviors.

The broader takeaway is not that one pathway explains schizophrenia or bipolar I disorder on its own. Serious mental illness is complex, and no single neurotransmitter system captures the full picture. Instead, the opioid pathway may be one important part of a larger biologic framework. For clinicians, researchers, and educators, paying attention to this system may help expand how psychiatric symptoms, comorbidities, and treatment responses are understood.

For patients and families, this kind of research can be helpful because it shows that psychiatry continues to evolve. Newer models of serious mental illness are looking beyond symptom labels alone and toward the biologic systems that may influence behavior, safety, function, and quality of life. Treatment decisions, however, should always remain individualized and should be made with a licensed clinician who can consider a person’s full history, current symptoms, risks, benefits, medications, and goals.

Sources and Disclosures

This blog post discusses themes from: Price RL. "The role of the opioid pathway in schizophrenia and bipolar I disorder." Pharmaphorum. Published February 16, 2026.

Funding: Not specified in the source article.

Conflict of interest: Dr. Richard Louis Price, the author of the source article and a member of Rebu's clinical leadership, has served as a speaker for AbbVie, Alkermes, Allergan, Axsome, Biogen, Bristol-Myers Squibb, Idorsia, Intracellular, Janssen, Jazz, Lundbeck, Neuronetics, Otsuka, Sage, Supernus, Teva, and Vanda.

Medical disclaimer: This blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to recommend or promote any specific medication, therapy, provider, or treatment plan. Medication and treatment decisions should be made by a licensed clinician based on an individual patient’s history, symptoms, risks, benefits, and clinical needs.